|
S.N. Tolpygina
Place of loop diurethics in treatment of chronic heart failure
|
№6 / 2017
|
|
Yu.V. Konev, L.B. Lazebnik, S.V. Levchenko, L.I. Yefremov
Endotoxin and endothelial dysfunction in patients with heart failure
|
№3 / 2017
|
|
A.G. Yevdokimova, Ye.V. Kovalenko, V.V. Yevdokimov, O.A. Shuiskaya
Potentials for the use of diuretic therapy in the clinic of internal diseases
|
№2 / 2017
|
|
A.S. Simbirtseva
Community-acquired pneumonia in patients with decompensated chronic heart failure
|
№2 / 2017
|
|
I.I. Shaposhnik
Modern aspects of diagnosis and treatment of chronic heart failure: what’s new?
|
№1 / 2017
|
|
M.Ye. Statsenko, S.V. Turkina, N.N. Shilina, M.A. Kosivtsova
Potentials for the additional medical correction using cytoprotectors in patients with chronic heart failure and nonalcoholic fatty liver disease
|
№1 / 2017
|
|
N.T. Vatutin, A.S. Smirnova, Ye.S. Gasendich
The evaluation of lipid profile in patients with chronic heart failure and concomitant chronic obstructive pulmonary disease
|
№6 / 2016
|
|
V.V. Cheltsov
Torasemide and furosemide: similarities and differences
|
№5 / 2016
|
|
S.N. Tolpygina
Place of eplerenone in the therapy of cardiovascular diseases
|
№5 / 2016
|
|
M.Ye. Statsenko, S.V. Turkina, I.A. Tyshchenko, S.V. Fabritskaya
Application of Mildronate in patients with comorbidity: focus on cardioneurology
|
№5 / 2016
|
|
V.V. Cheltsov, Yu.Sh. Gushina, T.S. Illarioniva, E.А. Korovyakova, A.E. Moiseeva, A.P. Pereversev, Ye.Yu. Stefanenko, S.K. Ziryanov
Angiotensin II receptor blockers: focus on cardesartan
|
№4 / 2016
|
|
V.V. Cheltsov, A.I. Martynov, Yu.Sh. Gushchina, T.S. Illarionova, E.A. Korovyakova
Metabolic therapy in chronic heart failure
|
№4 / 2016
|
Русский
